Camurus

Camurus AB (STO: CAMX) is a Swedish science-led biopharmaceutical company focused on developing and commercializing innovative long-acting medicines for the treatment of severe and chronic conditions. Founded in 1991, Camurus is headquartered in Lund, Sweden and has over 225 employees across offices in Europe, Australia and the US. The company reported total revenues of SEK 390 million in Q1 2024.

Camurus' product portfolio and pipeline include:

• Buvidal - A weekly and monthly buprenorphine depot injection for the treatment of opioid dependence, approved in multiple markets including Europe and Australia

• Brixadi/Brixadi - A weekly and monthly buprenorphine depot injection for opioid use disorder, approved in the US in May 2023

• CAM2029 (Oclaiz) - An investigational octreotide depot injection for acromegaly and neuroendocrine tumors, currently under regulatory review

• CAM2043 - An investigational treprostinil depot injection for pulmonary arterial hypertension

• episil - An oral liquid for the treatment of oral pain associated with oral mucositis

Camurus' proprietary FluidCrystal drug delivery technology platform is used to develop its long-acting injectable formulations. The company's shares are listed on the Nasdaq Stockholm exchange under the ticker "CAMX" and it moved to the Large Cap segment in December 2023. Camurus has partnerships with pharmaceutical companies including Braeburn for the commercialization of Brixadi in the US.